Introduction {#S0001}
============

Premature coronary artery disease (CAD) is a major cause of mortality and morbidity. In 2002, a Danish study showed that the incidence of CAD among people between 30 and 54 of age was 1% for men and 0.4% for women per year.[@CIT0001] Increased serum low-density lipoprotein-cholesterol (LDL-C) level is a major risk factor for CAD and thus the main target for its prevention.[@CIT0001] However, an acute exposure to high levels of serum LDL-C is not sufficient to determine the CAD onset. Indeed, prolonged exposure time to elevated levels of LDL-C is the main risk factor for acute coronary syndrome.[@CIT0002]

Familial Hypercholesterolemia (FH) is an inherited disorder of lipid metabolism characterized by high levels of LDL-C, and subsequent early CAD development. In northern Europe, the prevalence of FH in the general population is thought to be approximately 1/200.[@CIT0003]

The most common causes of FH are mutations in *LDL-receptor* (*LDLR), Apolipoprotein B* (*APOB*) and *proprotein convertase subtilisin/kexin type 9* (*PCSK9*) genes,[@CIT0003]--[@CIT0005] but a genetic diagnosis is reached only in 40--70% of cases.[@CIT0006] The frequency of FH-causing mutations at Northern European general population level was estimated to be 0.3% while the frequency of clinical FH is estimated to be 0.5%.[@CIT0003],[@CIT0007] This discrepancy suggests that approximately 40% of individuals with clinical diagnosis of FH do not have causative mutations in the three FH genes. For these individuals, it has been suggested that a polygenic form of the disease, rather than a monogenic, is the cause for the raised LDL-C levels. The polygenic form of FH can be defined based on a weighted LDL-C-raising gene score (SNP score) calculated by the presence of common LDL-C-raising alleles, each affecting LDL-C levels by only a small extent, identified by the Global Lipid Genetics Consortium.[@CIT0008]

Early drug treatment with lipid-lowering medications prevents the onset of cardiovascular disease.[@CIT0009],[@CIT0010] Therefore, the early identification of FH patients is crucial to start an effective prevention strategy.

It is estimated that FH explains 20% of premature CAD cases in individuals with familial clustering.[@CIT0011],[@CIT0012] Many studies describe the prevalence of clinical FH in individuals with premature CAD.[@CIT0013]--[@CIT0016] The clinical diagnosis is a very useful tool for general population screening. However, it shows limitations in identifying FH patients with a causing mutation. Genetic diagnosis is the gold standard to identify individuals with FH, and it allows the family screening also in individuals with borderline/moderately high serum LDL-C levels. With this study, we examined the prevalence of genetically determined FH in 66 individuals with premature CAD (\<50 years of age for men and \<55 years of age for women).

Patients and methods {#S0002}
====================

Selection criteria {#S0002-S2001}
------------------

A total of 218 patients who underwent coronary angiography with suspected premature acute coronary syndrome (age \<50 years for men and \<55 years for women) were identified at Sahlgrenska University Hospital between 2008 and 2013. To all of them, it was offered to test for FH by DNA analysis and it was explained that identification of an FH-causing mutation in the patient may help early identification and treatment of family members with FH to prevent a myocardial infarction. Although repeated letters and telephone calls, there was a poor compliance to the study. Specifically, 66 patients out of 218 (30%) underwent genetic screening to identify FH causing mutations. Of these, 49 had a confirmed diagnosis of premature CAD after coronary angiography. The study conforms to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the regional ethics committee of Gothenburg (Dnr 486--13). All subjects gave their written informed consent to participate in the study.

Data collection {#S0002-S2002}
---------------

All patients were given a questionnaire to complete and underwent a physical and clinical examination at the admittance. Specifically, we collected information about family and personal history, drug therapy and habits. Blood samples were collected and serum lipid levels (including total cholesterol, LDL-C, HDL-C and triglycerides) were determined by routine techniques at the admittance, at the Laboratory for Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg. LDL-C levels before treatment were available in 91% individuals (60 out of 66). LDL-C levels for those patients in whom the pretreatment values were not available (n=6) were quantified based on the estimated effect of the different statins.[@CIT0017] The diagnosis of cardiovascular disease was established based on coronary angiography finding. The Dutch Lipid Clinic Network score was calculated at the admittance as previously described.[@CIT0003]

Sequencing {#S0002-S2003}
----------

DNA was isolated from whole blood and targeted sequenced using SEQPRO LIPO RS (Progenika Biopharma, Derio, Spain, <http://www.progenika.com/>) as previously described.[@CIT0006] The 3 main FH-related genes were sequenced, namely *LDLR, APOB* and *PCSK9*.

SNP score calculation for polygenic hypercholesterolemia assessment {#S0002-S2004}
-------------------------------------------------------------------

For patients negative for FH-causing mutations, the LDL-raising SNP score was calculated using weighted sums for six selected SNPs.[@CIT0008] Genotyping for the 6 SNPs was performed in duplicate by TaqMan 5ʹ-nuclease assays (Life Technologies, Carlsbad, CA) with a concordance between duplicates and a success rate of 100%. All genotypes were all in Hardy-Weinberg equilibrium.

Potential polygenic FH was defined has a SNP score of ≥0.83 representing the top quintile score.

Statistical analysis {#S0002-S2005}
--------------------

Continuous variables are shown as means ± standard deviations and categorical variables as numbers and proportions. *p*-values were calculated by Mann--Whitney non-parametric test for independent samples for continuous variables, or by Fisher exact test for categorical variables. Statistical analyses were performed using the IBM Statistical Package for Social Sciences (version 20.0; IBM SPSS Inc., Chicago, IL, USA). Two-sided *p*-values \<0.05 were considered statistically significant.

Results {#S0003}
=======

Characteristics of the study cohort {#S0003-S2001}
-----------------------------------

The study cohort included 66 individuals with diagnosis of premature acute coronary event (\<50 years of age for men and \<55 years of age for women) who underwent a coronary angiography between 2008 and 2013 in one of the three coronary units at Sahlgrenska University Hospital in Gothenburg. Clinical characteristics of the study cohort are shown in [Table S1](#ST0001). Briefly, mean age of the study cohort was 43±6 years, BMI 27±5 kg/m^2^ and untreated LDL-C 3.71±1.45 mmol/L. Twelve (18%) individuals had diabetes, 40 (61%) had hypertension and 11 (17%) were smokers. Forty-one (62%) were finally diagnosed with myocardial infarction (STEMI or NSTEMI), 8 (12%) with unstable angina, stable angina or atherosclerosis, 9 (14%) with spasm angina and 8 (12%) with other diagnosis (non-atherosclerotic) including 2 systemic lupus erythematosus (SLE) vasculitis, 2 patent foramen ovale (PFO) with paradoxical embolizations, 1 anatomical variant, 1 Ehlers-Danlos syndrome, 1 drug-induced cardiotoxicity and 1 troponin T (TNT) elevation without clear cause. According to DLCN criteria, 9 (15%) individuals in the overall cohort had at least a probable FH diagnosis ([Table S1](#ST0001)). Of these, 2 were confirmed by genetic screening.

Prevalence of FH in patients with premature acute coronary syndrome {#S0003-S2002}
-------------------------------------------------------------------

We found a causative mutation in 3 individuals out of 66 screened (prevalence 4.5%). Compared to an estimated frequency of genetic FH of 0.3% in the general Northern European population, this would account for a 15-fold enrichment[@CIT0007] When considering individuals with a confirmed CAD after coronary angiography (myocardial infarction, unstable and stable angina and atherosclerosis), the FH mutation prevalence was 6.1% (3 out of 49). After excluding individuals with classical risk factors for CAD other than hypercholesterolemia (namely diabetes, hypertension and smoking), the FH mutation prevalence raised to 15.8% ([Figure 1](#F0001){ref-type="fig"}).Figure 1Prevalence of genetically determined familial hypercholesterolemia (FH). The expected prevalence of FH in the general population is 0.3%[@CIT0007] In our study cohort of premature cardiovascular disease, FH-causative mutations have been detected in 4.5% of the individuals accounting for a 15-fold enrichment compared to general population. When considering only individuals with a confirmed atherosclerotic disease, the prevalence increased to 6.1%. When individuals with other risk factors for cardiovascular disease (namely diabetes, smoking and hypertension) were further excluded from the analysis, the prevalence of genetically determined FH was 15.8% accounting for approximately a 53-fold enrichment compared to the general population. *P*-value calculated by Fisher exact test and referred to the comparison with the general population. \* *p*=0.015, \*\**p*=0.007, \*\*\**p*=0.0005.

The genetic analysis in the 3 FH individuals revealed 2 mutations in the *LDLR* gene (1 pathogenic stop codon and 1 splicing site classified as variant of uncertain significance) and 1 mutation in the *PCSK9* gene (pathogenic in-frame insertion resulting in a Leucine duplication and described as possible gain-of-function variant) ([Table 1](#T0001){ref-type="table"}).[@CIT0018],[@CIT0019]Table 1Identified FH-causing mutations in the study cohortGeneNucleotide substitutionAminoacidic changeExonClassDescription*PCSK9*c.60_65dupGCTGCT*p*.Leu22_Leu23dup1In-frame indelPathogenic*LDLR*c.296C\>G*p*.Ser99\*3Null allelePathogenic*LDLR*c.940_940+14del15NA6SplicingUnknown pathogenicity[^1]

Clinical characteristics of the study cohort stratified based on genetic diagnosis of FH are shown in [Table 2](#T0002){ref-type="table"}. Briefly, mean age was 34±16 years for FH individuals and 43±6 years for non-FH. There were no differences between FH and non-FH in blood sugar or blood pressure. None of the FH individuals was smoker, whilst 17% of the non-FH group had smoking habit. Untreated LDL-cholesterol levels in individuals with FH mutation were 2-fold higher than in those without mutation (7.17±2.67 vs 3.55±1.17 mmol/L, respectively, *P*\<0.005; [Figure 2](#F0002){ref-type="fig"}). When considering only individuals with angiography confirmed CAD, the LDL-C level difference between FH and non-FH individuals remained significant, with no differences in blood pressure and blood sugar levels between the groups. The mean LDL cholesterol level under ongoing statin treatment was 3.7 mmol/L for the FH group, accounting for a 45% reduction. Individuals with CAD and no FH mutation experienced an LDL-cholesterol level reduction of 0.8 mmol/L (from 3.6 to 2.8 mmol/L) under ongoing statin treatment.Table 2Clinical and biochemical characteristics of the study cohort stratified based on genetic diagnosis of FHUnaffectedFH*p*-valueN=63N=3Age, years43±634±160.325Men, n (%)25 (40)1 (81)0.827BMI, kg/m^2^27±534±70.132Creatinine, mmol/L86±9666±110.526Hemoglobin, mmol/L138±14146±210.505Glucose, mmol/L6.77±2.086.05±1.910.558Diabetes, n (%)12 (19)00.407Systolic blood pressure, mm Hg143±22135±210.584Diastolic blood pressure, mm Hg88±1580±00.529Hypertension, n (%)40 (63)00.057Statin Use Yes, n (%)49 (78)3 (100)0.614Smoke, n (%)11 (17)00.640SNP score0.63±0.23NA--Potential polygenic FH, n (%)14 (22)NA--**Current lipid levels**Total cholesterol, mmol/L4.86±1.145.93±1.270.119LDL-C, mmol/L2.94±1.094.2±1.610.140HDL-C, mmol/L1.25±0.421.23±0.320.925Triglycerides, mmol/L1.51±0.641.13±0.40.364**Lipid levels before treatment**Total cholesterol, mmol/L5.26±1.2410.3±3.820.003\***Diagnosis**Myocardial infarction, n (%)39 (62)2 (68)0.999Ubstable/stableangina/atherosclerosis, n (%)7 (11)1 (33)0.326Spasmangina, n (%)9 (14)----Other^a^, n(%)8 (13)----**Dutch Lipid Clinic Network criteria**Unlikely, n (%)30 (48)00.245Possible, n (%)24 (38)1 (33)0.999Probable, n (%)8 (13)1 (33)0.316Definite, n (%)1 (1)1 (33)0.090[^2][^3] Figure 2Untreated LDL-cholesterol levels in individuals without or with FH mutation. Patient with genetically determined FH had higher LDL-C before statin treatment. *p*-value calculated by Mann--Whitney non-parametric test for independent samples. Using linear regression adjusted for age, gender and BMI *p*=0.004.**Abbreviations:** FH, familial hypercholesterolemia; BMI, body mass index; LDL-C, low-density lipoprotein cholesterol.

Two of the 3 individuals with genetic FH diagnosis underwent PCI by stent delivery, one for STEMI and one for NSTEMI. These 2 individuals (both carriers of mutation on the *LDLR*) were 16 and 42 years old, respectively, with a family history of myocardial infarction. The third one had no new stenosis to be treated at the coronary angiography performed at inclusion, but had previously undergone PCI in 2003. This individual (carrier of the mutation on the *PCSK9*) was 42 years old and did not have family history of myocardial infarction.

All FH-negative individuals underwent genotyping for 6 LDL-raising SNPs and the weighted SNP score for polygenic hypercholesterolemia was calculated. The mean SNP score was 0.63±0.22. There was a tendency to positive correlation between SNP score and LDL-C, however not significant (Spearman r=0.173, *p*=0.180). Potential polygenic FH was defined as having a SNP score of ≥0.83 (corresponding to the top quintile score). Based on this definition, 14 patients out of 63 (22.3%) were considered as potential polygenic FH ([Table 2](#T0002){ref-type="table"}).

Discussion and conclusions {#S0004}
==========================

In the present study, we describe the prevalence of FH mutations in 66 young individuals with diagnosis of acute coronary event who underwent coronary angiography. We show that the prevalence of FH mutation in this cohort is 4.5%. This number is approximately 15 times higher than the expected mutation rate in the general population. We also show that, when considering only individuals with a confirmed atherosclerotic disease, the prevalence rises to 6.1%, and it further increases to 15.8% when excluding those with other cardiovascular risk factors. These data are consistent with a recently published work that showed an enrichment of FH mutation in individuals with acute coronary syndrome, LDL-C\>4.14 mmol/L at admission and under age 65.[@CIT0020] Compared to this study, our cohort is smaller, younger and was not selected based on any LDL-C threshold or ACS diagnosis. Our results are also consistent with the enrichment of mutations on *LDLR* described in individuals with premature myocardial infarction from the National Heart, Lung and Blood Institute's Exome Sequencing Project from the USA.[@CIT0021] In this paper, authors performed whole exome next-generation sequencing on DNA from individuals with and without premature MI. They found that carriers for FH mutations on *LDLR* had a prevalence of \~2% in their MI cohort. They also have shown that carriers of rare non-synonymous mutations on *LDLR* had a 4.2-fold increased risk for MI while carriers of null alleles had a more than 13-fold increased risk for MI.

Previously, a study performed on young individuals with myocardial infarction or stable angina pectoris from the Finnish region of North Karelia had shown a 9% prevalence of 2 FH mutations very common in that area due to founder effect.[@CIT0022] The authors tested only for the 2 specific mutations by PCR assay. At the time the study was conducted, criteria for myocardial infarction diagnosis were slightly different from now due to unavailability of high sensitive troponin test.

More recently, in a larger (n=231) cohort of young myocardial infarction individuals from UK, an FH prevalence of 1.3% was described after testing for 48 common mutations in the *LDLR* gene and NGS of *LDLR* only in those with LDL-C \>7 (mmol/L).[@CIT0023] The lower FH prevalence in this cohort might be explained by the fact that NGS sequencing was not performed on all the individuals and mutations in *PCSK9* and *APOB* genes were not tested either.

Furthermore, in a recent series of 255 German subjects with myocardial infarction before 60 years of age, a prevalence of FH mutations of 5% was found by NGS of *LDLR, APOB, PCSK9* and *STAP1* genes.[@CIT0024]

We hypothesize that the higher prevalence of FH mutation we find in CAD subjects in our cohort compared to the previous ones is due to our slightly different approach of selection, where we combine younger patients with a broad NGS sequencing of the 3 most important FH genes.

Despite the methodological differences between the aforementioned studies and our current work, all the findings are consistent with the hypothesis that FH prevalence in young individuals with CAD is much higher than in general population. This aspect has a two-fold importance. First, it identifies a population which would benefit from a broader genetic screening strategy. Second, it would allow implementing a very effective cascade screening strategy to strongly reduce cardiovascular risk in a high-risk population.

In the present study, we identified 2 mutations described as pathogenic (one stop gain in the *LDLR* gene and one in-frame insertion in the *PCSK9* gene),[@CIT0019],[@CIT0025] and 1 splicing site in the *LDLR* gene classified as variant of uncertain significance ([Table 1](#T0001){ref-type="table"}). The *LDLR* mutation of uncertain significance has been previously described to segregate with the phenotype in cascade screening, suggesting a pathogenic role.[@CIT0006] More specifically, the variant has been detected in 2/3 tested relatives of our proband: the 48-year-old father had LDL-C of 7.0 mmol/L; the 17-year-old brother, despite his young age, had LDL-C of 5.1 mmol/L.[@CIT0006] This finding strongly supports the pathogenicity of this variant.

Analyses of the clinical characteristics of the study cohort stratified by genetic FH diagnosis showed that those with FH mutation had as expected higher LDL-C levels both before and under statin treatment compared to those without. Treatment induced a 45% reduction in LDL-C for the FH group, while the non-FH group had only a 23% reduction. It is well established that FH subjects are usually treated more intensively with lipid-lowering medication. Interestingly, neither of the two groups was on target for secondary prevention. We did not find any other differences in risk factors among the two groups, most likely because of the small sample size. However, a tendency to lower blood sugar, triglycerides, diabetes prevalence, smoking and hypertension was present in those with FH.

Comparing the genetic test results with clinically determined FH diagnosis by DLCN criteria, we observed that 2 out of 3 genetically confirmed FH were classified as at least probable FH, while the third one as possible. On the other hand, one subject with definitive clinical diagnosis by DLCN had no genetic mutation. Our interpretation of these results is that the DLCN criteria is a very useful tool for general population screening, but a more effective strategy for genetic screening needs to be implemented to overcome the limits of clinical diagnosis. At the same time, further effort should be put into discovering new FH causative genes to reduce possible false negatives. The genetic diagnosis reduces the number of false negatives, allows screening of relatives and allows the identification of at-risk people early in life and before symptoms development. The early identification and treatment of FH individuals decreases the risk of CVD and results in life expectancy and quality of life for these at very-high-risk individuals compared to the general population. Furthermore, the genetic diagnosis gives a clear cut LDL-C target for treatment (2.5 mmol/L according to the ESC guidelines). These are major advantages of using FH genetic and why we support the utilization of the genetic screening together with the measurement of high LDL-C in clinical practice.

Using the LDL-raising SNP score, we identified 22% of the non-FH subjects as potential polygenic hypercholesterolemia. To our knowledge, there is not a SNP score cut-off that can be used to make a formal diagnosis of polygenic FH. In the present study, we used the SNP score top quintile as cut-off to identify potential polygenic FH subjects which does not correspond to a formal diagnosis. More studies need to be done to further characterize this subgroup of high-risk subjects and define which targets need to be achieved to optimize their treatment.

Finally, the analysis of diagnosis after coronary angiography showed a quite high prevalence of non-atherosclerotic diseases leading to the procedure. A high rate of spasm angina was detected, which is consistent with the young age and the high rate of female gender of our casuistic. Furthermore, we found 2 subjects with embolism from PFO and 2 with coronary artery engagement of SLE. Again, the high prevalence of non-atherosclerotic disease is in line with the young age of the cohort.

Major weaknesses of the current study are: the low number of participants and of carriers of FH mutations, and the absence of a control group which does not allow to make estimation of the risk in terms of Odds Ratio; the low attendance (30%), and the fact that an enrichment of FH cases in the studied group cannot be excluded. The attenders and non-attenders were of similar age and BMI. They had a similar lipid profile and similar diabetes prevalence. In a "worst case" scenario, the three FH patients were the only ones in the original group of 218. In that case, the FH frequency would be 1.4%, which still is 5 times higher than the expected mutation rate in the general population. This frequency would be even higher if only patients with atherosclerotic disease or subjects without other risk factors are analyzed.

In conclusion, we found a high prevalence of FH mutations in young subjects who underwent coronary angiography. Our results support the importance to implement an FH genetic screening program for patients at high risk for CAD and for their families, even independently of untreated LDL-C values. We also found that our cohort was generally undertreated in terms of LDL-C lowering targets.
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Table S1Clinical and biochemical characteristics of the study cohortN66Age, years43±6Men, n (%)26 (39)BMI, kg/m^2^27±5Creatinine, mmol/L85±94Hemoglobin, mmol/L138±14Glucose, mmol/L6.74±2.06Diabetes, n (%)12 (18)Systolic blood pressure, mm Hg142±22Diastolic blood pressure, mm Hg88±15Hypertension, n (%)40 (61)Statin Use Yes, n (%)52 (79)Smoke, n (%)11 (17)SNP score0.63±0.22**Current lipid levels**Total cholesterol, mmol/L4.93±1.16LDL-C, mmol/L3.01±1.14HDL-C, mmol/L1.25±0.41Triglycerides, mmol/L1.49±0.63**Lipid levels before treatment**Total cholesterol, mmol/L5.44±1.62LDL-C, mmol/L3.71±1.45**Dutch Lipid Clinic Network criteria**Unlikely, n (%)30 (45)Possible, n (%)25 (38)Probable, n (%)9 (14)Definite, n (%)2 (3)[^4]

[^1]: **Abbreviations:** FH, familial hypercholesterolemia; PCSK9, proprotein convertase subtilisin/kexin type 9; LDLR, LDL-receptor; NA, not available.

[^2]: **Notes:** Data are shown as mean ± standard deviation or as number and proportion for continuous and categorical variables, respectively. *p*-value calculated by Mann--Whitney non-parametric test for independent samples or by Fisher exact test. ^a^The group "other" includes including 2 systemic lupus erythematosus (SLE) vasculitis, 2 patent foramen ovale (PFO) with paradoxical embolizations, 1 anatomical variant, 1 Ehlers-Danlos syndrome, 1 drug-induced cardiotoxicity and 1 troponin T (TNT) elevation without clear cause. \*Using linear regression adjusted for age, gender and BMI *p*=2.4E-6.

[^3]: **Abbreviations:** FH, familial hypercholesterolemia; BMI, body mass index; NA, not available; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.

[^4]: **Note:** Data are shown as mean ± standard deviation or as number and proportion for continuous and categorical variables, respectively.

    **Abbreviations:** BMI, body mass index; SNP score, weighted LDL-C-raising gene score; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.
